![Christophe Arbet-Engels](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christophe Arbet-Engels
Technik-/Wissenschafts-/F&E-Leiter bei
ALTIMMUNE, INC.
Vermögen: 134 529 $ am 30.06.2026
Profil
Christophe Arbet-Engels is currently a Member of the Biochemical Sciences Tutors Board at Harvard University and will be Chief Medical Officer at Altimmune, Inc. starting in 2025.
Former positions include Vice President-Worldwide Medical at Biogen, Inc., Chief Medical Officer & EVP-Medical Affairs at Poxel SA from 2017 to 2019, Chief Medical Officer at Neurogastrx, Inc. from 2021 to 2023, Chief Medical Officer at Millendo Therapeutics, Inc. from 2020 to 2021, and Chief Medical Officer at X4 Pharmaceuticals, Inc. from 2023 to 2025.
Education includes an MBA from Rutgers State University of New Jersey, graduate studies at Université de Paris XI Paris Sud, and a doctorate from Université de Paris 5 René Descartes.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 12.02.2025 | 28’807 ( 0.03% ) | 134 529 $ | 30.06.2026 |
Aktive Positionen von Christophe Arbet-Engels
| Unternehmen | Position | Beginn |
|---|---|---|
| ALTIMMUNE, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2025 |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Christophe Arbet-Engels
| Unternehmen | Position | Ende |
|---|---|---|
| X4 PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 16.09.2025 |
Neurogastrx, Inc.
 Neurogastrx, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops transformative therapies for gastrointestinal disorders | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2023 |
| MILLENDO THERAPEUTICS | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2021 |
| POXEL | Technik-/Wissenschafts-/F&E-Leiter | 29.11.2019 |
| BIOGEN INC. | Corporate Officer/Principal | - |
Ausbildung von Christophe Arbet-Engels
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
91
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Poxel SA
 Poxel SA Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company, focuses on the development of novel treatments for serious chronic diseases | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rutgers State University of New Jersey
 Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Université de Paris XI Paris Sud
 Université de Paris XI Paris Sud Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Université de Paris 5 René Descartes
 Université de Paris 5 René Descartes Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Altimmune, Inc.
 Altimmune, Inc. BiotechnologyHealth Technology Develops biopharmaceuticals | Health Technology |
Neurogastrx, Inc.
Neurogastrx, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops transformative therapies for gastrointestinal disorders | Health Technology |
Millendo Therapeutics, Inc.
 Millendo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
X4 Pharmaceuticals, Inc.
 X4 Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
